|
Name |
methyl (2E,3E,5E,7E,9E)-2-ethylidene-11-[(1R,4S,5R)-4-hydroxy-4-(2-hydroxyethyl)-2-oxo-6-oxa-3-azabicyclo[3.1.0]hexan-1-yl]-4,10-dimethyl-11-oxoundeca-3,5,7,9-tetraenoate
|
Molecular Formula | C22H27NO7 | |
IUPAC Name* |
methyl (2E,3E,5E,7E,9E)-2-ethylidene-11-[(1R,4S,5R)-4-hydroxy-4-(2-hydroxyethyl)-2-oxo-6-oxa-3-azabicyclo[3.1.0]hexan-1-yl]-4,10-dimethyl-11-oxoundeca-3,5,7,9-tetraenoate
|
|
SMILES |
C/C=C(\C=C(/C)\C=C\C=C\C=C(/C)\C(=O)[C@@]12[C@@H](O1)[C@](NC2=O)(CCO)O)/C(=O)OC
|
|
InChI |
InChI=1S/C22H27NO7/c1-5-16(18(26)29-4)13-14(2)9-7-6-8-10-15(3)17(25)22-19(30-22)21(28,11-12-24)23-20(22)27/h5-10,13,19,24,28H,11-12H2,1-4H3,(H,23,27)/b8-6+,9-7+,14-13+,15-10+,16-5+/t19-,21-,22-/m0/s1
|
|
InChIKey |
OHWILISHWFHITP-OCKBFZBYSA-N
|
|
Synonyms |
NG-391; CHEMBL5074822
|
|
CAS | NA | |
PubChem CID | 11165983 | |
ChEMBL ID | CHEMBL5074822 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 417.5 | ALogp: | 2.4 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 126.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 30 | QED Weighted: | 0.17 |
Caco-2 Permeability: | -4.956 | MDCK Permeability: | 0.00001830 |
Pgp-inhibitor: | 0.991 | Pgp-substrate: | 0.012 |
Human Intestinal Absorption (HIA): | 0.754 | 20% Bioavailability (F20%): | 0.95 |
30% Bioavailability (F30%): | 0.978 |
Blood-Brain-Barrier Penetration (BBB): | 0.861 | Plasma Protein Binding (PPB): | 76.04% |
Volume Distribution (VD): | 1.678 | Fu: | 11.97% |
CYP1A2-inhibitor: | 0.021 | CYP1A2-substrate: | 0.704 |
CYP2C19-inhibitor: | 0.046 | CYP2C19-substrate: | 0.541 |
CYP2C9-inhibitor: | 0.069 | CYP2C9-substrate: | 0.03 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.126 |
CYP3A4-inhibitor: | 0.023 | CYP3A4-substrate: | 0.821 |
Clearance (CL): | 2.226 | Half-life (T1/2): | 0.91 |
hERG Blockers: | 0.322 | Human Hepatotoxicity (H-HT): | 0.809 |
Drug-inuced Liver Injury (DILI): | 0.795 | AMES Toxicity: | 0.943 |
Rat Oral Acute Toxicity: | 0.567 | Maximum Recommended Daily Dose: | 0.952 |
Skin Sensitization: | 0.95 | Carcinogencity: | 0.611 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.357 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003161 | 1.000 | D0FG6M | 0.255 | ||||
ENC005165 | 0.569 | D05QDC | 0.239 | ||||
ENC005164 | 0.569 | D00DKK | 0.239 | ||||
ENC003853 | 0.327 | D02DGU | 0.239 | ||||
ENC003854 | 0.327 | D0G3PI | 0.239 | ||||
ENC003852 | 0.297 | D0B1IP | 0.228 | ||||
ENC003807 | 0.278 | D0S7WX | 0.211 | ||||
ENC003585 | 0.278 | D0E9KA | 0.190 | ||||
ENC005401 | 0.266 | D0MY8N | 0.172 | ||||
ENC005400 | 0.264 | D0H2MO | 0.166 |